Marsavela, Gabriela
McEvoy, Ashleigh C.
Pereira, Michelle R.
Reid, Anna L.
Al-Ogaili, Zeyad
Warburton, Lydia
Khattak, Muhammad A.
Abed, Afaf
Meniawy, Tarek M.
Millward, Michael
Ziman, Melanie R.
Calapre, Leslie
Gray, Elin S. http://orcid.org/0000-0002-8613-3570
Funding for this research was provided by:
Western Australia Health Translational Network
Article History
Received: 8 March 2021
Revised: 28 June 2021
Accepted: 20 July 2021
First Online: 9 August 2021
Competing interests
: The following authors have received travel support from MAK [Merck Sharp and Dohme (MSD), Bristol-Myers Squibb (BMS) and Merck Serono], TMM [BMS, Novartis, AstraZeneca (AZ)] and ESG [MSD]. The following authors sit on advisory boards: TMM [BMS, MSD, Novartis, AZ] and MM [BMS, AZ, Roche, MSD]. All remaining authors have declared no competing interests.